KRAS and cyst: A cohort of 39 samples, comprising 33 cyst fluids and 6 blood plasma specimens, underwent thorough examination utilizing both the SiMoT array – targeting oncoproteins MUC1 and CD55, and oncogene KRAS – and the SIMOA SP‐X planar technology, focused exclusively on MUC1 and CD55.